Eisai Deal A Milestone On HUYA’s Evolving Road
This article was originally published in PharmAsia News
Executive Summary
A recent exclusive license agreement with Eisai for a cancer compound discovered by a Chinese company builds on HUYA Bioscience’s position as a leader in accelerating the global development of novel biopharmaceutical products originating in China, and the firm says it will continue to pursue further deals based on its database of 14,000 China-sourced compounds across multiple therapeutic areas.